Treatment of HER2-positive breast cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Berry, 2005, Effect of screening and adjuvant therapy on mortality from breast cancer, N Engl J Med, 353, 1784, 10.1056/NEJMoa050518
Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106
Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152
Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101
Joensuu, 2009, Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial, J Clin Oncol, 27, 5685, 10.1200/JCO.2008.21.4577
Perez, 2011, Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31, J Clin Oncol, 29, 3366, 10.1200/JCO.2011.35.0868
Slamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, 1273, 10.1056/NEJMoa0910383
Goldhirsch, 2013, 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial, Lancet, 382, 1021, 10.1016/S0140-6736(13)61094-6
Ryan, 2008, FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2, Oncologist, 13, 1114, 10.1634/theoncologist.2008-0816
Blumenthal, 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer, Clin Cancer Res, 19, 4911, 10.1158/1078-0432.CCR-13-1212
Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology – College of American Pathologists Clinical Practice Guideline Update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984
Gancberg, 2002, Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites, Ann Oncol, 13, 1036, 10.1093/annonc/mdf252
Gong, 2005, Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma, Cancer, 103, 1763, 10.1002/cncr.20987
Zidan, 2005, Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease, Br J Cancer, 93, 552, 10.1038/sj.bjc.6602738
Meng, 2004, HER-2 gene amplification can be acquired as breast cancer progresses, Proc Natl Acad Sci U S A, 101, 9393, 10.1073/pnas.0402993101
Lipton, 2005, Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy, Cancer, 104, 257, 10.1002/cncr.21202
Guarneri, 2008, Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management, Oncologist, 13, 838, 10.1634/theoncologist.2008-0048
Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205
Pusztai, 2010, Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis, Oncologist, 15, 1164, 10.1634/theoncologist.2010-0059
Di Leo, 2008, Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer, J Clin Oncol, 26, 5544, 10.1200/JCO.2008.16.2578
Paik, 2008, HER2 status and benefit from adjuvant trastuzumab in breast cancer, N Engl J Med, 358, 1409, 10.1056/NEJMc0801440
Perez, 2010, HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial, J Clin Oncol, 28, 4307, 10.1200/JCO.2009.26.2154
Pegram, 1997, The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells, Oncogene, 15, 537, 10.1038/sj.onc.1201222
Robert, 2006, Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer, J Clin Oncol, 24, 2786, 10.1200/JCO.2005.04.1764
Burstein, 2007, Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study, Cancer, 110, 965, 10.1002/cncr.22885
Andersson, 2011, Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study, J Clin Oncol, 29, 264, 10.1200/JCO.2010.30.8213
Yamamoto, 2008, A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial, Cancer Chemother Pharmacol, 61, 509, 10.1007/s00280-007-0497-5
Schaller, 2007, Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes, J Clin Oncol, 25, 3246, 10.1200/JCO.2006.09.6826
Baselga, 2010, Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy, J Clin Oncol, 28, 1138, 10.1200/JCO.2009.24.2024
Baselga, 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 366, 109, 10.1056/NEJMoa1113216
Theriault, 2013, Breast cancer, Version 3.2013, J Natl Compr Canc Netw, 11, 753, 10.6004/jnccn.2013.0098
Baselga, 2012, Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Presented at the 35th Annual San Antonio Breast Cancer Symposium, Abstr, S5-1, 2012
Bartsch, 2007, Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer, J Clin Oncol, 25, 3853, 10.1200/JCO.2007.11.9776
von Minckwitz, 2009, Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study, J Clin Oncol, 27, 1999, 10.1200/JCO.2008.19.6618
von Minckwitz, 2011, Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer, Eur J Cancer, 47, 2273, 10.1016/j.ejca.2011.06.021
Geyer, 2006, Lapatinib plus capecitabine for HER2-positive advanced breast cancer, N Engl J Med, 355, 2733, 10.1056/NEJMoa064320
Cameron, 2008, A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses, Breast Cancer Res Treat, 112, 533, 10.1007/s10549-007-9885-0
O'Regan, 2013, Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3)
Lewis Phillips, 2008, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate, Cancer Res, 68, 9280, 10.1158/0008-5472.CAN-08-1776
Krop, 2010, Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer, J Clin Oncol, 28, 2698, 10.1200/JCO.2009.26.2071
Burris, 2011, Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy, J Clin Oncol, 29, 398, 10.1200/JCO.2010.29.5865
Krop, 2012, A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine, J Clin Oncol, 30, 3234, 10.1200/JCO.2011.40.5902
Perez, 2010, Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of randomized, multicenter, open-label phase 2 study
Hurvitz SADL, Kocsis J, et al. Trastuzumab emtansine (T-DM1) versus trastuzumab plus docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976).
Verma, 2012, Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, 367, 1783, 10.1056/NEJMoa1209124
Blackwell, 2010, Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer, J Clin Oncol, 28, 1124, 10.1200/JCO.2008.21.4437
Blackwell, 2012, Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study, J Clin Oncol, 30, 2585, 10.1200/JCO.2011.35.6725
Dieras VHN, Albain K, et al. A phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results.
Cortes, 2012, Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer, J Clin Oncol, 30, 1594, 10.1200/JCO.2011.37.4207
Kaufman, 2009, Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study, J Clin Oncol, 27, 5529, 10.1200/JCO.2008.20.6847
Huober, 2012, Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – results of the eLEcTRA trial, Breast, 21, 27, 10.1016/j.breast.2011.07.006
Johnston, 2009, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer, J Clin Oncol, 27, 5538, 10.1200/JCO.2009.23.3734
Gori, 2007, Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors, Oncologist, 12, 766, 10.1634/theoncologist.12-7-766
Bachelot, 2013, Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study, Lancet Oncol, 14, 64, 10.1016/S1470-2045(12)70432-1
Spielmann, 2009, Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial, J Clin Oncol, 27, 6129, 10.1200/JCO.2009.23.0946
Perez, 2011, Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer, J Clin Oncol, 29, 4491, 10.1200/JCO.2011.36.7045
Gianni, 2011, Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial, Lancet Oncol, 12, 236, 10.1016/S1470-2045(11)70033-X
Pivot XRG, Bonnefoi H, et al. PHARE trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer.
Gonzalez-Angulo, 2009, High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller, J Clin Oncol, 27, 5700, 10.1200/JCO.2009.23.2025
Curigliano, 2009, Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer, J Clin Oncol, 27, 5693, 10.1200/JCO.2009.22.0962
Banerjee, 2010, Management of small HER2-positive breast cancers, Lancet Oncol, 11, 1193, 10.1016/S1470-2045(10)70119-4
Baselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3
Rimawi, 2013, Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006, J Clin Oncol, 31, 1726, 10.1200/JCO.2012.44.8027
Goss, 2013, Results of a randomized, double-blind, multicenter, placebo controlled study of adjuvant lapatinib in women with early-stage Erb2-overexpressing breast cancer, Lancet Oncol, 14, 88, 10.1016/S1470-2045(12)70508-9
Yen, 2000, Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis, Oncogene, 19, 3460, 10.1038/sj.onc.1203685
Epstein, 2002, HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF), Breast Cancer Res Treat, 76, S143
2009, Hurvitz Sea: final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment in HER2-amplified advanced breast cancer
Buzdar, 2005, Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer, J Clin Oncol, 23, 3676, 10.1200/JCO.2005.07.032
Untch, 2010, Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study, J Clin Oncol, 28, 2024, 10.1200/JCO.2009.23.8451
Untch, 2011, Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups, J Clin Oncol, 29, 3351, 10.1200/JCO.2010.31.4930
Untch, 2012, Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial, Lancet Oncol, 13, 135, 10.1016/S1470-2045(11)70397-7
Gianni, 2012, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 25, 10.1016/S1470-2045(11)70336-9
Prowell, 2012, Pathological complete response and accelerated drug approval in early breast cancer, N Engl J Med, 366, 2438, 10.1056/NEJMp1205737
Rabindran, 2004, Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase, Cancer Res, 64, 3958, 10.1158/0008-5472.CAN-03-2868
Burstein, 2010, Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer, J Clin Oncol, 28, 1301, 10.1200/JCO.2009.25.8707
Saura, 2011, Safety and efficacy of neratinib in combinastion with capecitabine in patients with ErbB2-positive beast cancer, Cancer Res, 71
Chow LGS, Hershman DL, et al. Efficacy and safety of neratinib (HKI-272) in combination with paclitaxel in HER2+ metastatic breast cancer.
Awada, 2013, Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy, Ann Oncol, 24, 109, 10.1093/annonc/mds284
Lin, 2012, A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab, Breast Cancer Res Treat, 133, 1057, 10.1007/s10549-012-2003-y
Baselga, 2011, Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer, Oncologist, 16, 12, 10.1634/theoncologist.2011-S1-12
Lauring, 2013, The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer, J Natl Compr Canc Netw, 11, 670, 10.6004/jnccn.2013.0086
Wang, 2011, PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib, BMC Cancer, 11, 248, 10.1186/1471-2407-11-248
Nahta, 2004, The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells, Cancer Res, 64, 2343, 10.1158/0008-5472.CAN-03-3856
Scheuer, 2009, Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models, Cancer Res, 69, 9330, 10.1158/0008-5472.CAN-08-4597
Topalian, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Curr Opin Immunol, 24, 207, 10.1016/j.coi.2011.12.009
Stagg, 2011, Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy, Proc Natl Acad Sci U S A, 108, 7142, 10.1073/pnas.1016569108
Higgins, 2012, Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood, Clin Cancer Res, 18, 3462, 10.1158/1078-0432.CCR-11-2696
Schneeweiss, 2013, Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), Ann Oncol, 24, 2278, 10.1093/annonc/mdt182